These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25312239)

  • 21. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
    Feldman G; Walker RR; Brooks J; Mehta R; Crater G
    Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
    Donohue JF; Kalberg C; Shah P; Beerahee M; Mehta R; Gunawan R; Church A
    J Clin Pharmacol; 2014 Nov; 54(11):1214-20. PubMed ID: 24895108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Umeclidinium in patients with COPD: a randomised, placebo-controlled study.
    Trivedi R; Richard N; Mehta R; Church A
    Eur Respir J; 2014 Jan; 43(1):72-81. PubMed ID: 23949963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.
    Miravitlles M; Gáldiz JB; Huerta A; Villacampa A; Carcedo D; Garcia-Rio F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():123-32. PubMed ID: 26848262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients.
    Decramer M; Maltais F; Feldman G; Brooks J; Harris S; Mehta R; Crater G
    Respir Physiol Neurobiol; 2013 Jan; 185(2):393-9. PubMed ID: 23026438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
    Maltais F; Milot J
    Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
    Vogelmeier C; Banerji D
    Ther Adv Respir Dis; 2011 Jun; 5(3):163-73. PubMed ID: 21511677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
    Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
    Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
    Mastrodicasa MA; Droege CA; Mulhall AM; Ernst NE; Panos RJ; Zafar MA
    Expert Opin Investig Drugs; 2017 Feb; 26(2):161-174. PubMed ID: 28004591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.
    Riley JH; Tabberer M; Richard N; Donald A; Church A; Harris SS
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1873-80. PubMed ID: 27578968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M; Molimard M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
    Goyal N; Beerahee M; Kalberg C; Church A; Kilbride S; Mehta R
    Clin Pharmacokinet; 2014 Jul; 53(7):637-48. PubMed ID: 24756395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
    Calzetta L; Matera MG; Cazzola M
    Eur J Pharmacol; 2015 Aug; 761():168-73. PubMed ID: 25981302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
    Joos GF
    Expert Opin Investig Drugs; 2010 Feb; 19(2):257-64. PubMed ID: 20047505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Rogliani P; Rinaldi B; Cazzola M
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):35-41. PubMed ID: 25382021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Umeclidinium/Vilanterol: first global approval.
    Scott LJ; Hair P
    Drugs; 2014 Mar; 74(3):389-95. PubMed ID: 24532124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current optimization of combined therapy for chronic obstructive pulmonary disease].
    Popova EN
    Ter Arkh; 2015; 87(12):107-110. PubMed ID: 27022659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update on LAMA/LABA combinations for COPD.
    Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.
    Matera MG; Rogliani P; Calzetta L; Cazzola M
    Drug Saf; 2016 Jun; 39(6):501-8. PubMed ID: 26924197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.